Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a…
By B. Hutten, M. Prins, M. Gent, Jeffrey S. Ginsberg, J. Tijssen, H. Büller. Journal of Clinical Oncology, 2000
768 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hepatology, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/58900cbb1e6bf6b34eb2af37465f647a06e34b72
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Internal Medicine
Citations in the corpus
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). (2018, neutral): “9 Currently receiving cancer treatment§ 142 (70) 140 (69) Chemotherapy 120 (85) 113 (81) Radiotherapy 10 (7) 6 (4) Targeted therapy 22 (15) 21 (15) Endocrine therapy 15 (11) 15 (11) Primary tumor type Bladder 4 (2) 10 (5) Brain 2 (1) 1 (1) Breast 20 (10) 20 (10) Cancer unknown primary 3 (2) 3 (1) Ch”
- Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism (2008, background): “thromboembolic complications and major bleeding during anticoagulant treatment than those without malignancy.(315,316) These risks correlate with the extent of cancer.”
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. (2002, background): “*Uterus (13 patients [numbers in parentheses are numbers of patients]), kidney (9), ovary or testicle (8), bladder (9), prostate (8).”
- Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. (2002, positive): “2 rate ratio of major bleeding compared with patients free of cancer.(7) These findings strongly call for alternative treatments that should be evaluated in cancer patients with venous thromboembolism.”
- Epidemiology of cancer-associated venous thrombosis. (2013, background): “However, such treatment comes with a disadvantage of an increased risk of bleeding, which is especially pronounced in cancer patients.(46,53,54) In a prospective follow-up of 842 DVT patients, Prandoni et al investigated bleeding rates during anticoagulant treatment.”
- [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “Active cancer is a major risk factor for recurrence of VTE, the rate of recurrence being approximately 20% during the first 12 months after the index event.(364,365) Therefore, patients with cancer are can-”
- ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “Active cancer is a major risk factor for recurrence of VTE, the rate of recurrence being approximately 20% during the first 12 months after the index event.(364,365) Therefore, patients with cancer are can-”